For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
Dr. Julia E. McGuinness
Advertisement
McGuinness is a medical oncologist and serves as an assistant professor of medicine within the Division of Hematology/Oncology at Columbia University Irving Medical Center, Columbia University Herbert Irving Comprehensive Cancer Center, located in New York.
Articles by Dr. Julia E. McGuinness
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Pancreatic Cancer on the Rise Among Younger Adults
2
FDA Approves Stoboclo and Osenvelt as Biosimilars for Some Cancers
3
Covering Every FDA Oncology Approval From October 2025
4
Why ‘There is Hope’ For Patients With Pancreatic Cancer
5
